Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) FCF Margin (2021 - 2025)

Janux Therapeutics (JANX) has disclosed FCF Margin for 5 consecutive years, with 137.46% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 38031.0% to 137.46% in Q3 2025 year-over-year; TTM through Dec 2025 was 822.35%, a 40515.0% decrease, with the full-year FY2025 number at 822.35%, down 40515.0% from a year prior.
  • FCF Margin was 137.46% for Q3 2025 at Janux Therapeutics, up from 517.77% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1423.68% in Q1 2021 to a low of 1440.78% in Q2 2023.
  • A 5-year average of 532.33% and a median of 538.22% in 2021 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -217372bps in 2022, then skyrocketed 133036bps in 2024.
  • Janux Therapeutics' FCF Margin stood at 598.14% in 2021, then grew by 18bps to 491.0% in 2022, then increased by 14bps to 423.24% in 2023, then dropped by -22bps to 517.77% in 2024, then soared by 73bps to 137.46% in 2025.
  • Per Business Quant, the three most recent readings for JANX's FCF Margin are 137.46% (Q3 2025), 517.77% (Q3 2024), and 110.42% (Q2 2024).